

# THE LANCET

## HIV

### Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Neesgaard B, Greenberg L, Miró JM, et al. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium. *Lancet HIV* 2022; published online June 7. [https://doi.org/10.1016/S2352-3018\(22\)00094-7](https://doi.org/10.1016/S2352-3018(22)00094-7).

## **Appendix:**

### **The International Multicohort Consortium of Infectious Disease (RESPOND) study group:**

**AIDS Therapy Evaluation in the Netherlands Cohort (ATHENA):** F Wit, M vd Valk, M Hillebregt, Stichting HIV Monitoring (SHM), Amsterdam, Netherlands

**The Australian HIV Observational Database (AHOD):** M Law, K Petoumenos, N Rose, J Hutchinson, UNSW Sydney, Sydney, Australia

**Austrian HIV Cohort Study (AHIVCOS):** R Zangerle, H Appoyer, Medizinische Universität Innsbruck, Innsbruch, Austria

**CHU Saint-Pierre:** S De Wit, M Delforge, Centre de Recherche en Maladies Infectieuses a.s.b.l., Brussels, Belgium

**EuroSIDA Cohort:** Gilles Wandeler, CHIP, Rigshospitalet, RegionH, Copenhagen, Denmark

**Frankfurt HIV Cohort Study:** C Stephan, M Bucht, Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany

**Georgian National AIDS Health Information System (AIDS HIS):National AIDS Health Information System (AIDS HIS):** N Chkhartishvili, O Chokoshvili, Infectious Diseases, AIDS and Clinical Immunology Research Center, Tbilisi, Georgia

**Italian Cohort Naive Antiretrovirals (ICONA):** A d'Arminio Monforte, A Rodano, A Tavelli, ASST Santi Paolo e Carlo, Milan, Italy; I Fanti, Icona Foundation, Milan, Italy

**Modena HIV Cohort:** C Mussini, V Borghi, Università degli Studi di Modena, Modena, Italy

**Nice HIV Cohort:** C Pradier, E Fontas, K Dollet, C Caissotti, Université Côte d'Azur et Centre Hospitalier Universitaire, Nice, France.

**PISCIS Cohort Study:** J Casabona, JM Miro, Centre Estudis Epidemiologics de ITS i VIH de Catalunya (CEEISCAT), Badalona, Spain

**Royal Free Hospital Cohort:** C Smith, F Lampe, M Johnson, F Burns, C Chaloner, Royal Free Hospital, University College London, London, United Kingdom

**San Raffaele Scientific Institute:** A Castagna, A Lazzarin, A Poli, Università Vita-Salute San Raffaele, Milano, Italy

**Swedish InfCare HIV Cohort:** A Sönnborg, K Falconer, V Svedhem, Karolinska University Hospital, Stockholm, Sweden

**Swiss HIV Cohort Study (SHCS):** H Günthard, B Ledergerber, H Bucher, K Kusejko, University of Zurich, Zurich, Switzerland

**University Hospital Bonn:** JC Wasmuth, J Rockstroh, Bonn, Germany

**University Hospital Cologne:** JJ Vehreschild, G. Fätkenheuer, M Stecher, N Schulze, B Franke, Cologne, Germany

**RESPOND Executive Committee:**

Lene Ryom\*, J Rooney, I McNicholl, V Vannappagari, H Garges, G Wandeler, M Law, R Zangerle, C Smith, S De Wit, J Lundgren, H Günthard

\*Chair

**RESPOND Scientific Steering Committee:**

J Lundgren\*, H Günthard\*, J Kowalska, D Raben, L Ryom, A Mocroft, J Rockstroh, L Peters, A Volny Anne, N Dedes, ED Williams, N Chkhartishvili, R Zangerle, M Law, F Wit, C Necsoi, G Wandeler, C Stephan, C Pradier, A D'Arminio Monforte, C Mussini, A Brugera, H Bucher, A Sönnborg, JJ Vehreschild, JC Wasmuth, C Smith, A Castagna, J Rooney, I McNicholl, V Vannappagari, H Garges

\*Chairs

**Community Representatives:**

Alain Volny-Anne, Nikos Dedes, Luis Mendaño (European AIDS Treatment Group), Esther Dixon Williams (UK)

**RESPOND Staff**

Coordinating Centre Staff: JF Larsen, B Neesgaard, O Fursa, N Jaschinski, D Raben, L Ryom, L Peters, ML Jakobsen, T Bruun, A Bojesen

Data Management Staff: EV Hansen, AK Traytel, TW Elsing, D Kristensen, T Weide

Statistical Staff: A Mocroft, L Greenberg, L Bansi-Matharu, A Pelchen-Matthews, K Petoumenos, N Rose, D. Byonanebye

Graphical design and illustrations: O Valdenmaiier

**Supplementary Table 1: Prior exposure as numbers, percentage and median cumulative exposure to specific drugs within different ART classes among individuals that did experience a CVD event during follow-up, stratified by INSTI exposed or not INSTI exposed during follow-u**

ARVs	exposure	INSTI exposed	Not INSTI exposed
		n = 242	n = 506
PIs (IDV,LPV/r, DRV/b)	n	159	311
	%	65.7 %	61.5%
	Median cumulative exposure, months (IQR)	56 (22-114)	58 (23-95)
NRTIs (ABC, DDI)	n	180	318
	%	74.4%	62.8%
	Median cumulative exposure, months (IQR)	72 (29-127)	79 (30-127)
NNRTIs (EFV)	n	103	245
	%	42.6%	48.4%
	Median cumulative exposure, months (IQR)	49 (17-112)	53 (17-115)

Abbreviations: PIs: protease inhibitors, ARVs: antiretroviral drugs, IDV: indinavir, LPV/r: ritonavir boosted lopinavir, DRV/b: cobicistat or ritonavir boosted darunavir, NRTI: nucleos(t)ide reverse transcriptase inhibitors, ABC: abacavir, DDI: Didanosine, NNRTI: non-nucleotide reverse transcriptase inhibitors, EFV: efavirenz, IQR: interquatile range, CVD: cardiovascular disease, INSTI: integrase inhibitor

**Supplementary Table 2: Prior exposure as numbers, percentage and median cumulative exposure to specific drugs within different ART classes among individuals that did not experience a CVD event during follow-up, stratified by INSTI exposed or not INSTI exposed during follow-up**

ARVs	exposure	INSTI exposed	Not INSTI exposed
		n = 13360	n = 15232
PIs (IDV,LPV/r, DRV/b)	n	6944	7507
	%	52.0%	49.3%
	Median cumulative exposure, months (IQR)	49 (19-96)	51 (20-96)
NRTIs (ABC, DDI)	n	7830	6202
	%	58.6%	40.7%
	Median cumulative exposure, months (IQR)	53 (26-111)	64 (26-111)
NNRTIs (EFV)	n	4637	6657
	%	34.7%	43.7%
	Median cumulative exposure, months (IQR)	56 (16-111)	60 (19-115)

Abbreviations: PIs: protease inhibitors, ARVs: antiretroviral drugs, IDV: indinavir, LPV/r: ritonavir boosted lopinavir, DRV/b: cobicistat or ritonavir boosted darunavir, NRTI: nucleos(t)ide reverse transcriptase inhibitors, ABC: abacavir, DDI: Didanosine, NNRTI: non-nucleotide reverse transcriptase inhibitors, EFV: efavirenz, IQR: interquatile range, CVD: cardiovascular disease, INSTI: integrase inhibitor